Pharmacodynamic studies of nitrofurantoin against common uropathogens

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 4, 2014, Pages 1076-1082

  Komp Lindgren, P ^a   Klockars, O ^a   Malmberg, C ^a   Cars, O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

PD; Urinary tract infections; UTIs

Indexed keywords

NITROFURANTOIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCUS FAECIUM; EPSILOMETER TEST; ESCHERICHIA COLI; IN VITRO STUDY; KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; STAPHYLOCOCCUS SAPROPHYTICUS; URINARY TRACT INFECTION; BACTERIAL INFECTION; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; THEORETICAL MODEL;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; NITROFURANTOIN; STAPHYLOCOCCUS SAPROPHYTICUS; URINARY TRACT INFECTIONS;

EID: 84926509405     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku494     Document Type: Article

References (29)

1. Al-Zarouni M, Senok A, Al-Zarooni N et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline. Med Princ Pract 2012; 21: 543-7.
2. Kashanian J, Hakimian P, Blute M Jr et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008; 102: 1634-7.
3. Garau J. Other antimicrobials of interest in the era of extendedspectrum β-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008; 14 Suppl 1: 198-202.
4. Gupta K, Hooton TM, Naber KG et al. Executive summary: international clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: 561-4.
5. Grabe M et al. Guidelines on Urological Infections from the European Association of Urology (EAU). 2010. http://www.uroweb.org/guidelines/.
6. Nicolle LE. Update in adult urinary tract infection. Curr Infect Dis Rep 2011; 13: 552-60.
7. Naber KG, Schito G, Botto H et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54: 1164-75.
8. Edlin RS, Shapiro DJ, Hersh AL et al. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol 2013; 190: 222-7.
9. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012; 39: 45-51.
10. Gupta K, Hooton TM, Roberts PL et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167: 2207-12.
11. Schmiemann G, Gágyor I, Hummers-Pradier E et al. Resistance profiles of urinary tract infections in general practice-an observational study. BMC Urol 2012; 12: 33.
12. McCalla DR, Reuvers A, Kaiser C. Mode of action of nitrofurazone. J Bacteriol 1970; 104: 1126-34.
13. McCalla DR, Reuvers A, Kaiser C. Breakage of bacterial DNA by nitrofuran derivatives. Cancer Res 1971; 31: 2184-8.
14. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother 1994; 33 Suppl A: 23-30.
15. Adkison KK, Vaidya SS, Lee DY et al. The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br J Clin Pharmacol 2008; 66: 233-9.
16. Richards WA, Riss E, Kass EH et al. Nitrofurantoin; clinical and laboratory studies in urinary tract infections. AMA Arch Intern Med 1955; 96: 437-50.
17. Gilbert DN. Urinary tract infections in patients with chronic renal insufficiency. Clin J Am Soc Nephrol 2006; 1: 327-31.
18. EUCAST. Rationale Documents From EUCAST: Nitrofurantoin. http://www.eucast.org/documents/rd/.
19. Amábile-Cuevas CF, Arredondo-García JL. Antimicrobial activity data in support of nitrofurantoin three times per day. J Antimicrob Chemother 2011; 66: 1652-3.
20. Löwdin E, Odenholt I, Bengtsson S et al. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrob Agents Chemother 1996; 40: 2478-82.
21. Odenholt I, Löwdin E, Cars O. In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium. Clin Microbiol Infect 2003; 9: 930-7.
22. Löwdin E, Odenholt-Tornqvist I, Bengtsson S et al. A new method to determine postantibiotic effect and effects of subinhibitory antibiotic concentrations. Antimicrob Agents Chemother 1993; 37: 2200-5.
23. Coulthard MG, Kalra M, Lambert HJ et al. Redefining urinary tract infections by bacterial colony counts. Pediatrics 2010; 125: 335-41.
24. EUCAST. Clinical Breakpoints. 2013. http://www.eucast.org/clinical_ breakpoints/.
25. Liu HY, Lin HC, Lin YC et al. Antimicrobial susceptibilities of urinary extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011; 44: 364-8.
26. Fournier D, Chirouze C, Leroy J et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect 2013; 43: 62-6.
27. Tasbakan MI, Pullukcu H, Sipahi OR et al. Nitrofurantoin in the treatment of extended-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents 2012; 40: 554-6.
28. Carroll G, Brennan RV, Jacques R. Furadantin: human blood level and urinary concentration. South Med J 1955; 48: 149-51.
29. Hultgren SJ, Schwan WR, Schaeffer AJ et al. Regulation of production of type 1 pili among urinary tract isolates of Escherichia coli. Infect Immun 1986; 54: 613-20.